Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1461822 | 0.80 | ALDH1A1 (0.41) | GAAALDH1A1CA12CA1CA9 | |
| SCHEMBL7549121 | 0.80 | CA12 (0.35) | GAACYP3A4ALDH1A1MAPK1CA12 | |
| SCHEMBL29674856 | 0.79 | ALDH1A1 (0.43) | GAATSHRCYP3A4ALDH1A1TP53 | |
| SCHEMBL22572996 | 0.79 | TSHR (0.44) | GAATSHRCYP3A4ALDH1A1TP53 | |
| SCHEMBL9387233 | 0.79 | ALDH1A1 (0.43) | GAATSHRCYP3A4ALDH1A1TP53 | |
| SCHEMBL4704877 | 0.79 | ALDH1A1 (0.43) | GAATSHRCYP3A4ALDH1A1TP53 | |
| SCHEMBL31246236 | 0.79 | TSHR (0.44) | GAATSHRCYP3A4ALDH1A1TP53 | |
| SCHEMBL8526012 | 0.76 | GAA (0.50) | GAATSHRCYP3A4ALDH1A1TP53 | |
| SCHEMBL21225128 | 0.75 | GAA (0.38) | GAATSHRCYP3A4ALDH1A1TP53 | |
| SCHEMBL102065 | 0.75 | THRB (0.48) | GAATSHRCYP3A4ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200039930-A1 | PROLINE AMIDE COMPOUNDS AND THEIR AZETIDINE ANALOGUES CARRYING A SPECIFICALLY SUBSTITUTED BENZYL RADICAL | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-02-06 | — | — | US | disclosed |
| US-20080200731-A1 | Polyhalogen-substituted cinnamic acids and cinnamic acid derivatives and a process for the preparation of polyhalogen-substituted cinnamic acids and cinnamic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2008-08-21 | — | — | US | disclosed |
| US-7381832-B2 | Polyhalogen-substituted cinnamic acids and cinnamic acid derivatives and a process for the preparation of polyhalogen-substituted cinnamic acids and cinnamic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2008-06-03 | — | — | US | disclosed |
| US-20050234264-A1 | Polyhalogen-substituted cinnamic acids and cinnamic acid derivatives and a process for the preparation of polyhalogen-substituted cinnamic acids and cinnamic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-10-20 | — | — | US | disclosed |
| US-6956129-B2 | Polyhalogen-substituted cinnamic acids and cinnamic acid derivatives and a process for the preparation of polyhalogen-substituted cinnamic acids and cinnamic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-10-18 | — | — | US | disclosed |
| EP-1362025-A2 | POLYHALOGEN-SUBSTITUTED CINNAMIC ACIDS AND CINNAMIC ACID DERIVATIVES AND A METHOD FOR PRODUCING THE SAME | Bayer Aktiengesellschaft (DE) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002066411-A2 | POLYHALOGEN-SUBSTITUTED CINNAMIC ACIDS AND CINNAMIC ACID DERIVATIVES AND A METHOD FOR PRODUCING THE SAME | BAYER AKTIENGESELLSCHAFT (DE) | 2002-08-29 | — | — | WO | disclosed |
| US-20020115885-A1 | Polyhalogen-substituted cinnamic acids and cinnamic acid derivatives and a process for the preparation of polyhalogen-substituted cinnamic acids and cinnamic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039930-A1 | PROLINE AMIDE COMPOUNDS AND THEIR AZETIDINE ANALOGUES CARRYING A SPECIFICALLY SUBSTITUTED BENZYL RADICAL | HTR2C, HTR2A, HTR5A | GAA 3069/4885TSHR 458/4885CYP3A4 665/4885 |
| US-20050234264-A1 | Polyhalogen-substituted cinnamic acids and cinnamic acid derivatives and a process for the preparation of polyhalogen-substituted cinnamic acids and cinnamic acid derivatives | DDT, DDC, NISCH | GAA 129/4885TSHR 4347/4885CYP3A4 25/4885 |
| US-20080200731-A1 | Polyhalogen-substituted cinnamic acids and cinnamic acid derivatives and a process for the preparation of polyhalogen-substituted cinnamic acids and cinnamic acid derivatives | DDT, DDC, NISCH | GAA 129/4885TSHR 4347/4885CYP3A4 25/4885 |
| US-20020115885-A1 | Polyhalogen-substituted cinnamic acids and cinnamic acid derivatives and a process for the preparation of polyhalogen-substituted cinnamic acids and cinnamic acid derivatives | DDT, DDC, NISCH | GAA 122/4885TSHR 4435/4885CYP3A4 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.